OlympiA interim analysis (follow-up 6.1 years): in germline BRCA1/2 high-risk HER2-negative early breast cancer, 1 year of adjuvant olaparib vs placebo sustained invasive disease-free survival benefit (HR 0.65) and improved overall survival (HR 0.72; 6-year 87.5% vs 83.2%).
RCTn = 1,836
Garber et al. Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial